Literature DB >> 20950953

Atypical clinical behavior of p16-confirmed HPV-related oropharyngeal squamous cell carcinoma treated with radical radiotherapy.

Shao Hui Huang1, Bayardo Perez-Ordonez, Fei-Fei Liu, John Waldron, Jolie Ringash, Jonathan Irish, Bernard Cummings, Lillian L Siu, John Kim, Ilan Weinreb, Andrew Hope, Patrick Gullane, Dale Brown, Willa Shi, Brian O'Sullivan.   

Abstract

PURPOSE: To report atypical clinical behavior observed in human papillomavirus (HPV)-related oropharyngeal carcinoma (OPC) treated with radiotherapy. METHODS AND MATERIALS: A retrospective cohort study was conducted for all newly diagnosed OPC cases treated with radiotherapy on July 1, 2003 to April 30, 2009. HPV positivity was determined by p16 immunostaining in tumors. The incidence of additional malignancies and the pattern of distant metastases (DMs) were compared between the HPV-positive (HPV+) and HPV-negative (HPV-) cohorts.
RESULTS: HPV status was evaluated in 318 of 613 consecutive OPC cases (52%), showing 236 HPV+ and 82 HPV- patients. Compared with HPV-, HPV+ cases were less likely to have additional malignancies (prior: 11% vs. 20%, p = 0.038; synchronous: 1% vs. 9%, p = 0.001; metachronous: 6% vs. 16%, p = 0.003). Whereas the majority (10 of 12) of HPV- additional head-and-neck (HN) mucosal malignancies were in the oral cavity, there was none (0 of 7) in the HPV+ cohort (p < 0.001). HPV+ synchronous HN second primaries (SPs) were in the supraglottis, post-cricoid, and nasopharynx; metachronous HN SPs were in the glottis, supraglottis, and ethmoid plus glottis/post-cricoid region. All SPs that could be tested were HPV+. There was no difference in DM rate (10% vs. 15%, p = 0.272), but HPV+ DMs were more likely to involve multiple organs (46% vs. 0%, p = 0.005) and unusual sites.
CONCLUSIONS: This study reports atypical clinical behavior seen in HPV+ OPC, including multicentric lesions in HN mucosa and DM to multiple organs and unusual sites. The frequency of these events is low, but they may have clinical implications. The routine assessment of HPV status for all OPC is warranted.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20950953     DOI: 10.1016/j.ijrobp.2010.08.031

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  62 in total

1.  Adoption of transoral robotic surgery compared with other surgical modalities for treatment of oropharyngeal squamous cell carcinoma.

Authors:  Jennifer R Cracchiolo; Benjamin R Roman; David I Kutler; William I Kuhel; Marc A Cohen
Journal:  J Surg Oncol       Date:  2016-07-08       Impact factor: 3.454

2.  Two for the price of one: Prevalence, demographics and treatment implications of multiple HPV mediated Head and Neck Cancers.

Authors:  William Strober; Sachie Shishido; Burton Wood; James S Lewis; Krystle Kuhs; Robert L Ferris; Daniel L Faden
Journal:  Oral Oncol       Date:  2019-11-22       Impact factor: 5.337

3.  Clinical and molecular characteristics of HNSCC patients with brain metastases: a retrospective study.

Authors:  Olcay Cem Bulut; Katja Lindel; Henrik Hauswald; Regine Brandt; Frederick Klauschen; Janina Wolf; Thomas Wolf; Peter K Plinkert; Christian Simon; Wilko Weichert; Albrecht Stenzinger
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-08-29       Impact factor: 2.503

4.  Human papillomavirus and overall survival after progression of oropharyngeal squamous cell carcinoma.

Authors:  Carole Fakhry; Qiang Zhang; Phuc Felix Nguyen-Tan; David Rosenthal; Adel El-Naggar; Adam S Garden; Denis Soulieres; Andy Trotti; Vilija Avizonis; John Andrew Ridge; Jonathan Harris; Quynh-Thu Le; Maura Gillison
Journal:  J Clin Oncol       Date:  2014-06-23       Impact factor: 44.544

5.  Improved outcomes in PI3K-pathway-altered metastatic HPV oropharyngeal cancer.

Authors:  Glenn J Hanna; Alec Kacew; Nicole G Chau; Priyanka Shivdasani; Jochen H Lorch; Ravindra Uppaluri; Robert I Haddad; Laura E MacConaill
Journal:  JCI Insight       Date:  2018-09-06

6.  Orbital mass as first presentation of metastatic p16-positive oropharyngeal squamous cell carcinoma.

Authors:  J Corbett; D Wilke; J Trites; N Lamond
Journal:  Curr Oncol       Date:  2017-12-20       Impact factor: 3.677

7.  [Plasma circulating tumor HPV-DNA as a potential biomarker to identify recurrence of HPV-associated oropharyngeal carcinoma].

Authors:  Alexander Rühle; Nils H Nicolay
Journal:  Strahlenther Onkol       Date:  2020-07       Impact factor: 3.621

8.  Distant metastasis in p16-positive oropharyngeal squamous cell carcinoma: a critical analysis of patterns and outcomes.

Authors:  P Sinha; W T Thorstad; B Nussenbaum; B H Haughey; D R Adkins; D Kallogjeri; J S Lewis
Journal:  Oral Oncol       Date:  2013-11-06       Impact factor: 5.337

Review 9.  Epidemiology of HPV-associated oropharyngeal cancer.

Authors:  Kristen B Pytynia; Kristina R Dahlstrom; Erich M Sturgis
Journal:  Oral Oncol       Date:  2014-01-22       Impact factor: 5.337

10.  Increase in primary surgical treatment of T1 and T2 oropharyngeal squamous cell carcinoma and rates of adverse pathologic features: National Cancer Data Base.

Authors:  Jennifer R Cracchiolo; Shrujal S Baxi; Luc G Morris; Ian Ganly; Snehal G Patel; Marc A Cohen; Benjamin R Roman
Journal:  Cancer       Date:  2016-03-11       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.